透過您的圖書館登入
IP:3.145.186.147
  • 期刊

【論文摘要】Synthesis and Imaging Evaluation of Gastro-Resistant Insulin Receptor-Binding Peptide in the Diabetic Mice

摘要


Introduction: Diabetes is characterized by hyperglycemia, which is caused by a defect in insulin secretion, insulin resistance, or a combination of both. Gastro-Resistant Insulin Receptor-Binding Peptides (IRBP) have insulin receptor-binding and blood glucose-lowering activities. And Gastro-Resistant characteristic was suitable for oral use. Peptide synthesis and imaging evaluation experiments in type 1 and type 2 diabetic mice could be helpful for drug development. Methods: We developed the IRBP peptide synthesizing under a variety of conditions by using the CEM Liberty automated microwave peptide synthesizer. The bifunctional chelating agent S-2-(4-isothiocyanatobenzyl)-diethylenetriamine pentaacetic acid (p-SCN-Bn-DTPA) was linked to the peptide and labelled with In-111. DTPA-IRBP peptides were purified by high-performance liquid chromatography (HPLC) and confirmed by mass spectrometry (MS) and micro-single photon emission computed tomography/computed tomography (microSPECT/CT) imaging was performed in normal, type 1, and type 2 diabetic mice. Results: The purity of DTPA-IRBP peptide was > 95%. Before microSPECT imaging test, stability of In-111-DTPAIRBP peptide was evaluated in normal mice serum and in phosphate-buffered saline (PBS) at 37°C and stable during 4 h. After oral injection of In-111-DTPA-IRBP peptide (500 μCi) for 20 min, the mice were detected by microSPECT/CT. The accumulation activity in gastro-intestinal tracts was evaluated. Conclusions: The IRBP peptide was successfully synthesized by CEM Liberty peptide synthesizer and p-SCN-Bn-DTPA was linked to IRBP peptide successfully. In-111-DTPA-IRBP peptide is produced with high yield and stability. The initial imaging test also showed good stability in diabetic mice and longer duration biodistribution evaluation may be needed.

關鍵字

無資料

延伸閱讀